相似文献
1
Expanding Access and Reducing Prices for Drugs to Prevent HIV: Should Government Enforce Its Patent Rights Against the Pharmaceutical Industry?
JAMA. 2020 Mar 3;323(9):821-822. doi: 10.1001/jama.2019.22357.
2
TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
Seton Hall Law Rev. 2016;46(3):883-909.
3
Taking TRIPS to India--Novartis, patent law, and access to medicines.
N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.
4
Amendments to the Canadian Patent Act to address drug access: is help on the way?
Food Drug Law J. 2005;60(3):459-70.
5
Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Dev World Bioeth. 2014 Aug;14(2):83-91. doi: 10.1111/dewb.12050. Epub 2014 Apr 21.
6
Drug firms lose patent rights lawsuit against South Africa's government.
Lancet. 2001 Apr 28;357(9265):1347. doi: 10.1016/S0140-6736(00)04541-4.
7
Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
Dev World Bioeth. 2017 Aug;17(2):90-99. doi: 10.1111/dewb.12124. Epub 2016 Oct 4.
8
Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Conn J Int Law. 2002 Spring;17(2):157-248.
9
Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Houst J Int Law. 2002;24(2):227-78.
10
[HIV antiretroviral agents: new threats to accessibility in developing countries].
Rev Med Suisse. 2005 Dec 14;1(45):2956.
引用本文的文献
1
Antibiotic Economies: The Economisation of Antibiotic Use in Australia and Implications for the Mitigation of Antimicrobial Resistance.
Sociol Health Illn. 2025 Feb;47(2):e70011. doi: 10.1111/1467-9566.70011.
Zotero 插件